D&D Pharmatech

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • USD 766M net foreign currency exposure at FY2025-end, down from USD 3.57B at FY2024-end
• • USD 10% exchange rate move impacts pre-tax net income by ±KRW 76.6M in FY2025, down from ±KRW 357M in FY2024

Management Discussion & Analysis

• • Revenue KRW 4.298B (-62.42% YoY), operating loss KRW 33.993B (-35.88%), net loss KRW 23.980B (-18.67%)
• • MASH therapy DD01 segment drove R&D focus; continued US Phase 2 clinical trial with clinical progress and data acquisition

Business Overview

• • Core business: peptide-based innovative drug R&D with GLP-1 obesity oral drugs and MASH treatment DD01, plus neurodegenerative and fibrosis therapy pipelines
• • DD01 MASH drug clinical 2nd phase in US reached primary endpoint June 2025; China partner Salubris got obesity IND approval Dec 2024

What are the latest D&D Pharmatech DART filings in 2026?

D&D Pharmatech (KRX code 347850) has filed an annual report on March 20, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did D&D Pharmatech file its most recent annual report?

D&D Pharmatech filed its most recent annual report on March 20, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is D&D Pharmatech's KRX stock code?

D&D Pharmatech's KRX stock code is 347850. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 347850 to look up all D&D Pharmatech disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does D&D Pharmatech file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for D&D Pharmatech.

Where can I find D&D Pharmatech financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from D&D Pharmatech annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.